A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...
Children exposed to antiretroviral (ARV) therapy in utero and not exposed to HIV showed no difference in language development at 5 years of age compared with unexposed children, based on new data from ...
An end-to-end digital PrEP pathway appeared to improve accessibility, inclusivity, and service satisfaction among LGBTQ+ ...
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...